Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Jaroslaw Cisowski *Sahlgrenska Center for Cancer Research, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg, Gothenburg SE-405 30, Sweden.ORCID 0000-0001-7788-3903
Ahmed Ezat El Zowalaty *Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.ORCID 0000-0001-6177-6142
Sama I Sayin *Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.ORCID 0000-0003-1993-3487
Piotr Czarnota *Faculty of Biochemistry, Biophysics and Biotechnology, Department of General Biochemistry, Jagiellonian University, Krakow 30-387, Poland.ORCID 0009-0005-2304-8781
Tomasz GromowskiFaculty of Biochemistry, Biophysics and Biotechnology, Department of General Biochemistry, Jagiellonian University, Krakow 30-387, Poland.ORCID 0000-0001-6905-2886
Ella A EklundSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.
Muhammad KashifDepartment of Medicine, Karolinska Institutet, Huddinge SE-141 83, Sweden.
Angana A H PatelSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.ORCID 0000-0001-5499-9655
Antonio MolinaroWallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg SE-405 30, Sweden.
Per LindahlWallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg SE-405 30, Sweden.
Clotilde WielSahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.
Volkan I Sayin *Sahlgrenska Center for Cancer Research, Department of Surgery, Institute of Clinical Sciences, University of Gothenburg, Gothenburg SE-405 30, Sweden.ORCID 0000-0002-5225-8260
Martin O Bergo *Department of Medicine, Karolinska Institutet, Huddinge SE-141 83, Sweden.ORCID 0000-0002-6915-7140
Funding
Cancerfonden (Swedish Cancer Society) 23-3062Narodowe Centrum Nauki (NCN) 2020/37/B/NZ4/02533Vetenskapsrådet (VR) 2018-02318Vetenskapsrådet (VR) 2019-01507Vetenskapsrådet (VR) 2022-00971Vetenskapsrådet (VR) 2024-03027
6 · The paper itself
Abstract
The MEK-ERK pathway is a key driver of hepatocellular carcinoma (HCC) pathogenesis, and BRAF mutations, particularly BRAF
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
BRAF inhibition increases TGFβ2 production and stimulates metastasis in mice with endogenous BRAF · full record | Socratic